Table 4.
Subgroup analysis by TNM stage, tumor site and histological type for the MTHFR C677T polymorphisms.
| CT vs CC* | TT vs CC* | |
|---|---|---|
| ORa (95%CI) | ORa (95%CI) | |
| Gastric cancer | ||
| TNM stage | ||
| I+II | 0.810(0.685-0.958) | 0.933(0.750-1.161) |
| III+IV | 0.844(0.685-1.040) | 0.792(0.597-1.050) |
| Tumor site | ||
| Cardiac | 0.906(0.569-1.442) | 0.967(0.531-1.760) |
| Non-cardiac | 0.811(0.696-0.944) | 0.876(0.717-1.070) |
| Histological type | ||
| Intestinal | 0.815(0.680-0.978) | 0.865(0.681-1.099) |
| Diffuse | 0.832(0.672-1.031) | 0.868(0.654-1.153) |
| Mixed | 0.827(0.600-1.139) | 1.111(0.748-1.652) |
| Colorectal cancer | ||
| TNM stage | ||
| I+II | 0.947(0.775-1.158) | 0.854(0.652-1.119) |
| III+IV | 0.823(0.679-0.997) | 0.667(0.510-0.871) |
| Tumor site | ||
| Colon | 0.942(0.744-1.146) | 0.727(0.553-0.952) |
| Rectum | 0.888(0.636-1.073) | 0.855(0.666-1.099) |
ORa, adjusted for age and sex; CC*, CC as reference group